<DOC>
	<DOCNO>NCT03047681</DOCNO>
	<brief_summary>An association mast cell outcomes patient undergo transcatheter aortic valve replacement ( TAVR ) study knowledge . We aim characterize tryptase level dynamic TAVR ; Demonstrate whether tryptase level post-TAVR use prognostic marker .</brief_summary>
	<brief_title>Tryptase Level Marker Complications Transcatheter Aortic Valve Replacement</brief_title>
	<detailed_description>Inflammation know detrimental effect outcome patient myocardial infarction ( MI ) [ 1 , 2 ] well reperfusion injury ( RI ) [ 3 ] . Previous trial show correlation extent inflammatory response postoperative complication bad outcome patient undergo cardiac surgery [ 4 , 5 , 6 , 7 ] include valve replacement [ 8 ] . Transcatheter aortic valve replacement ( TAVR ) may associate inflammation [ 5 , 9 ] well . A possible mechanism may responsible , tissue injury due mechanical trauma , vascular complication , possible suboptimal organ perfusion due bleeding , ventricular pacing , balloon valvuloplasty , deployment , post-dilatation , reposition valve prosthesis [ 10 ] . Accumulating data show peri-procedural inflammation associate bad outcome complication TAVR [ 11 , 12 , 13 , 14 , 15 ] , may predict increased mortality patient TAVR [ 16 , 17 , 18 , 19 , 20 ] . Inflammation complex process include many type cell include mast cell . The association mast cell , part inflammatory process , RI thoroughly study . Mast cell link RI many organ [ 21 ] , contribute insult myocardium . This association suggest animal model [ 22 , 23 , 24 ] well recent human trial show tryptase , abundant protease find mast cell granule , elevate ST segment elevation myocardial infarction ( STEMI ) patient treat primary percutaneous coronary intervention ( PCI ) [ 25 ] . Therefore , reasonable assume mast cell may role inflammation process involve patient undergo TAVR . Moreover , association mast cell may use predict adverse outcome . To knowledge , association mast cell outcomes patient undergo TAVR study . METHODS Peripheral venous blood 30 patient undergoing TAVR withdrawn examine tryptase level , marker mast cell activity . Blood sample take 0 hour ( procedure ) second sample take 2 hour post-procedure . CRP examine patient pre post TAVR . Tryptase level examine 10 patient undergoing diagnostic coronary angiography . PRIMARY OBJECTIVE We aim : 1 . Characterize tryptase level dynamic TAVR 2 . Demonstrate whether tryptase level post-TAVR use prognostic marker . Primary outcome - mortality 1 year Secondary outcomes - Major complication 7 day 30 day , include death , major stroke , acute kidney injury , paravalvular regurgitation , permanent pacemaker implantation , coronary artery obstruction , heart block , vascular injury , pericardial hemorrhage . REFERENCES : 1 . Patel MR , Mahaffey KW , Armstrong PW , Weaver WD , Tasissa G , Hochman JS , Todaro TG , Malloy KJ , Rollins S , Theroux P , Ruzyllo W , Nicolau JC , Granger CB . Prognostic usefulness white blood cell count temperature acute myocardial infarction ( CARDINAL Trial ) . Am J Cardiol 2005 ; 95:614-618 . 2 . Theroux P , Armstrong PW , Mahaffey KW , Hochman JS , Malloy KJ , Rollins S , Nicolau JC , Lavoie J , Luong TM , Burchenal J , Granger CB . Prognostic significance blood marker inflammation patient ST-segment elevation myocardial infarction undergo primary angioplasty effect pexelizumab , C5 inhibitor : substudy COMMA trial . Eur Heart J 2005 ; 26:1964-1970 . 3 . Ibáñez B , Heusch G , Ovize M , Van de Werf F. Evolving therapy myocardial ischemia/reperfusion injury . J Am Coll Cardiol . 2015 Apr 14 ; 65 ( 14 ) :1454-71 . 4 . Cremer J , Martin M , Redl H , Bahrami S , Abraham C , Graeter T , Haverich A , Schlag G , Borst HG . Systemic inflammatory response syndrome cardiac operation . Ann Thorac Surg 1996 ; 61:1714-1720 . 5 . Lindman BR , Goldstein JS , Nassif ME , Zajarias A , Novak E , Tibrewala A , Vatterott AM , Lawler C , Damiano RJ , Moon MR , Lawton JS , Lasala JM , Maniar HS . Systemic inflammatory response syndrome transcatheter surgical aortic valve replacement . Heart 2015 Apr ; 101 ( 7 ) :537-45 . 6 . Kilger E , Heyn J , Beiras-Fernandez A , et al . Stress dose hydrocortisone reduce systemic inflammatory response patient undergoing cardiac surgery without cardiopulmonary bypass . Minerva Anestesiol . 2011 ; 77:268-274 . 7 . Clarizia NA , Manlhiot C , Schwartz SM , et al . Improved outcomes associate intraoperative steroid use high-risk pediatric cardiac surgery . Ann Thorac Surg . 2011 ; 91 ( 4 ) :1222-1227 . 8 . Prat C , Ricart P , Ruyra X , et al . Serum concentration procalcitonin cardiac surgery . J Card Surg . 2008 ; 23 ( 6 ) :627-632 . 9 . Stähli BE1 , Grünenfelder J , Jacobs S , Falk V , Landmesser U , Wischnewsky MB , Lüscher TF , Corti R , Maier W , Altwegg LA . Assessment inflammatory response transfemoral transcatheter aortic valve implantation compare transapical surgical procedure : pilot study . J Invasive Cardiol . 2012 Aug ; 24 ( 8 ) :407-11 . 10 . Sinning JM1 , Scheer AC , Adenauer V , Ghanem A , Hammerstingl C , Schueler R , Müller C , Vasa-Nicotera M , Grube E , Nickenig G , Werner N. Systemic inflammatory response syndrome predicts increase mortality patient transcatheter aortic valve implantation . Eur Heart J . 2012 Jun ; 33 ( 12 ) :1459-68 . 11 . Masson JB1 , Kovac J , Schuler G , Ye J , Cheung A , Kapadia S , Tuzcu ME , Kodali S , Leon MB , Webb JG . Transcatheter aortic valve implantation : review nature , management , avoidance procedural complication . JACC Cardiovasc Interv . 2009 Sep ; 2 ( 9 ) :811-20 . 12 . Toggweiler S1 , Webb JG . Challenges transcatheter aortic valve implantation . Swiss Med Wkly . 2012 Dec 17 ; 142 : w13735 . 13 . Rettig TC1 , Rigter S1 , Nijenhuis VJ2 , van Kuijk JP2 , ten Berg JM2 , Heijmen RH3 , van de Garde EM4 , Noordzij PG . The systemic inflammatory response syndrome predict short-term outcome transapical transcatheter aortic valve implantation . J Cardiothorac Vasc Anesth . 2015 Apr ; 29 ( 2 ) :283-7 . 14 . Krumsdorf U1 , Chorianopoulos E , Pleger ST , Kallenbach K , Karck M , Katus HA , Bekeredjian R. C-reactive protein kinetics prognostic value transfemoral aortic valve implantation . J Invasive Cardiol . 2012 Jun ; 24 ( 6 ) :282-6 . 15 . Van Linden A1 , Kempfert J , Rastan AJ , Holzhey D , Blumenstein J , Schuler G , Mohr FW , Walther T. Risk acute kidney injury minimally invasive transapical aortic valve implantation 270 patient . Eur J Cardiothorac Surg . 2011 Jun ; 39 ( 6 ) :835-42 ; discussion 842-3 . 16 . Zahn R , Gerckens U , Grube E , Linke A , Sievert H , Eggebrecht H , Hambrecht R , Sack S , Hauptmann KE , Richardt G , Figulla HR , Senges J. Transcatheter aortic valve implantation : first result multi-centre real-world registry . Eur Heart J 2011 ; 32:198-204 17 . Sinning JM , Ghanem A , Steinhauser H , Adenauer V , Hammerstingl C , Nickenig G , Werner N. Renal function predictor mortality patient percutaneous transcatheter aortic valve implantation . JACC Cardiovasc Interv 2010 ; 3:1141-1149 . 18 . Nuis RJ , van Mieghem NM , Tzikas A , Piazza N , Otten AA , Cheng J , van Domburg RT , Betjes M , Serruys PW , de Jaegere PP . Frequency , determinants prognostic effect acute kidney injury red blood cell transfusion patient undergoing transcatheter aortic valve implantation . Catheter Cardiovasc Interv 2011 ; 77:881-889 . 19 . Aregger F , Wenaweser P , Hellige GJ , Kadner A , Carrel T , Windecker S , Frey FJ . Risk acute kidney injury patient severe aortic valve stenosis undergo transcatheter valve replacement . Nephrol Dial Transplant 2009 ; 24:2175-2179 . 20 . Bagur R , Webb JG , Nietlispach F , Dumont E , De Larochelliere R , Doyle D , Masson JB , Gutierrez MJ , Clavel MA , Bertrand OF , Pibarot P , Rodes-Cabau J . Acute kidney injury follow transcatheter aortic valve implantation : predictive factor , prognostic value , comparison surgical aortic valve replacement . Eur Heart J 2010 ; 31:865-874 . Van Linden A , Kempfert J , Rastan AJ , Holzhey D , Blumenstein J , Schuler G , Mohr FW , Walther T. Risk acute kidney injury minimally invasive trans-apical aortic valve implantation 270 patient . Eur J Cardiothorac Surg 2011 ; 39:835-42 . 21 . Yang MQ1 , Ma YY , Ding J , Li JY . The role mast cell ischemia reperfusion injury . Inflamm Res . 2014 Nov ; 63 ( 11 ) :899-905 . 22 . Masini E , Giannella E , Bianchi S , Mannaioni PF : Histamine lactate dehydrogenase ( LDH ) release ischemic myocardium guinea-pig . Agents Actions 1987 ; 20:281-283 . 23 . Masini E1 , Bianchi S , Gambassi F , Palmerani B , Pistelli A , Carlomagno L , Mannaioni PF . Ischemia reperfusion injury histamine release isolate perfused guinea-pig heart : pharmacological intervention . Agents Actions . 1990 Apr ; 30 ( 1-2 ) :198-201 24 . Frangogiannis NG1 , Perrard JL , Mendoza LH , Burns AR , Lindsey ML , Ballantyne CM , Michael LH , Smith CW , Entman ML . Stem cell factor induction associate mast cell accumulation canine myocardial ischemia reperfusion . Circulation . 1998 Aug 18 ; 98 ( 7 ) :687-98 . 25 . Shaomin Chen , Di Mu , Ming Cui , Chuan Ren , Shu Zhang , Lijun Guo , Wei Gao . Dynamic change clinical significance serum tryptase level STEMI patient treat primary PCI . Biomarkers . 2014 Nov ; 19 ( 7 ) :620-4 .</detailed_description>
	<criteria>18 year age old Capable give informed consent Undergoing TAVR</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>TAVR</keyword>
	<keyword>tryptse</keyword>
	<keyword>mast</keyword>
</DOC>